CIRM
CALIFORNIA'S STEM CELL AGENCY

DISCOVERY | TRANSLATIONAL | CLINICAL

EDUCATION | INFRASTRUCTURE

Report on November 27th, 2017
Joint Transition and Science Subcommittee Meeting
Jonathan Thomas, Chairman ICOC

Goal

- To identify strategies to sustain the Agency beyond Proposition 71 funding.

Timeline

- June 29, 2017 – JT established Transition Subcommittee

- September 18, 2017 – first Transition Subcommittee meeting

- September 28, 2017 – presentation to ICOC re September 18 discussion

- November 27, 2017 – Joint Transition and Science Subcommittee meeting

- December 14, 2017 – presentation to ICOC re November 27 discussion

Agenda for Joint Subcommittee Meeting

- Review of September 18 Transition Subcommittee meeting

- Best option: Citizen-led bond measure in November 2020 – Bob Klein

- Spending remaining CIRM funds until then – Dr. Millan

- Bridge funding until November 2020 – JT and Bob

- Other fundraising options/goals

Recommended Options

- Citizen-led bond measure in 2020

- Bridge funding - $222M

- Other fundraising options/goals

Citizen-Led Bond Measure

- Citizen-led bond measure November 2020
  - Bob Klein

- Legislative option November 2020
  - Back-up option; will continue to update legislators and constitutional candidates

Fundraising Scenario:
Preserves CIRM Value Proposition
Increases "Shots on Goal" & Pipeline

	2018	2019	2020
CLIN	**$130 M**	**$130 M**	**$114 M** (8 More Trials; 4 More Late Stage Clinical Candidates)
TRAN	**$30 M**	**$25 M**	**$40 M** (8 More TRAN Candidates)
DISC	**$10 M**	**$9.25 M**	**$20 M** (12 Additional DISC2 Projects)
EDUC	**$750 K**	**$0 K**	**$16 M** (5 New Training Awards)
INFR	ongoing	ongoing	**$16 M** (2 New Alpha Clinics)
ADMIN	ongoing	ongoing	**$16M**

CIRM
CALIFORNIA STEM CELL AGENCY

Maintaining Momentum and CIRM's Value Proposition

Supplemental Fundraising

Given recent successes in the field, donors are interested in co-funding one or many projects

- Criteria
- Will piggy back off GWG recommendations and Board approval